Fintel reports that on October 8, 2025, Oppenheimer maintained coverage of Ionis Pharmaceuticals (NasdaqGS:IONS) with a Outperform recommendation.
Analyst Price Forecast Suggests 6.50% Upside
As of September 30, 2025, the average one-year price target for Ionis Pharmaceuticals is $74.51/share. The forecasts range from a low of $43.43 to a high of $100.80. The average price target represents an increase of 6.50% from its latest reported closing price of $69.96 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Ionis Pharmaceuticals is 990MM, an increase of 4.86%. The projected annual non-GAAP EPS is -2.58.
What is the Fund Sentiment?
There are 697 funds or institutions reporting positions in Ionis Pharmaceuticals. This is an increase of 22 owner(s) or 3.26% in the last quarter. Average portfolio weight of all funds dedicated to IONS is 0.22%, an increase of 35.24%. Total shares owned by institutions increased in the last three months by 1.86% to 195,329K shares. 
The put/call ratio of IONS is 0.42, indicating a bullish outlook.
What are Other Shareholders Doing?
T. Rowe Price Investment Management holds 16,049K shares representing 10.07% ownership of the company. In its prior filing, the firm reported owning 16,176K shares , representing a decrease of 0.79%. The firm increased its portfolio allocation in IONS by 24.02% over the last quarter.
Capital World Investors holds 12,540K shares representing 7.87% ownership of the company. In its prior filing, the firm reported owning 12,362K shares , representing an increase of 1.42%. The firm increased its portfolio allocation in IONS by 19.19% over the last quarter.
Bellevue Group holds 7,853K shares representing 4.93% ownership of the company. No change in the last quarter.
FDGRX - Fidelity Growth Company Fund holds 7,671K shares representing 4.81% ownership of the company. In its prior filing, the firm reported owning 7,595K shares , representing an increase of 0.98%. The firm increased its portfolio allocation in IONS by 3.07% over the last quarter.
Wellington Management Group Llp holds 6,346K shares representing 3.98% ownership of the company. In its prior filing, the firm reported owning 8,416K shares , representing a decrease of 32.63%. The firm decreased its portfolio allocation in IONS by 86.93% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
